MaxCyte, Inc.

As of March 22, 2022, MaxCyte, Inc. is considered risky and overvalued with a Price to Book Value of 1.15, an EV to EBITDA ratio of -2.00, a negative ROCE of 80.39%, and a year-to-date return of -61.06%, significantly underperforming the S&P 500's 12.22%.

As of March 22, 2022, MaxCyte, Inc. is considered overvalued and rated as risky due to poor financial metrics, including a Price to Book Value of 1.15, an EV to Sales ratio of 2.43, and a negative ROCE of -80.39%, despite performing better than some peers like Scholar Rock in terms of EV to EBITDA.

As of March 21, 2025, MaxCyte, Inc. exhibits a strong bearish trend, confirmed by multiple indicators including MACD, moving averages, and Bollinger Bands across weekly and monthly time frames.

As of March 2022, the management team of MaxCyte, Inc. includes Dr. J. Stark Thompson (Non-Executive Independent Chairman), Mr. Douglas Doerfler (President and CEO), and Mr. Ronald Holtz (Senior VP and Chief Accounting Officer), along with several Non-Executive Independent Directors on the Board.

MaxCyte, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, specializing in cell-based medicines. As of March 2025, it reported net sales of $10 million and a net loss of $10 million, with a market cap of $228.58 million.

As of Jun 18, MaxCyte, Inc. has a market capitalization of 228.58 million, with net sales of 37.67 million and a net profit of -41.80 million over the latest four quarters. Shareholder's funds are 206.25 million, and total assets are 239.47 million.